None listed
Conditions
Interventions
amlodipine / atorvastatin 5mg / 10mg Type of group
Amlodipine / atorvastatin 5mg / 10mg will be administered for 14 weeks
Group name:Amlodipine / atorvastatin 10mg / 80mg Type of group
Amlodipine / atorvastatin 10mg / 80mg will be administered for 14 weeks
Sponsors
PFIZER S.A.,
Eligibility
Inclusion criteria
Inclusion criteria: Clinical diagnosis of high blood pressure and low density lipoprotein cholesterol levels, which require medication.
Exclusion criteria
Exclusion criteria: Patients with blood pressure maintained adequately to the target with or without medication Patients currently receiving treatment with amlodipine and atorvastatin or who are not at blood pressure or lipid level while taking the highest dose of amlodipine or atorvastatin, respectively
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Outcome name:Levels of blood pressure and lipids. Measure:The therapeutic efficacy of amlodipine / atorvastatin by evaluation of the percentage of subjects trying to treat, who achieve the goals of treatment of both blood pressure and lipids Timepoints:14 day | — |
Secondary
| Measure | Time frame |
|---|---|
| Outcome name:summary of serious adverse events (EASs) or other available safety information including all serious unexpected adverse events related to the drug Measure:To assess the safety of dual therapy with titration of the doses of amlodipine and atorvastatin to achieve therapeutic goals in TA and LDL-C. Timepoints:throughout the study | — |
Countries
Arabia Saudi, Argentina, Australia, Brazil, Chile, Guatemala, India, Indonesia, Israel, Korea North, Mexico, Morocco, Pakistan, Peru, Philippines, Singapore, South Africa, Taiwan, Thailand, Tunisia, Turkey, United Arab Emirates
Outcome results
None listed